Abstract: Objective In this study, the effects of lienal polypeptide injection (LPI) combined postoperative chemotherapy on patients with breast cancer were explored. Methods Totally 201 cases with primary breast cancer from January 2014 to December 2017 received adjuvant chemotherapy, including 109 cases with estrogen receptor positive (ER+) breast cancer and 92 cases with ER negative (ER-) breast cancer in Shanxi Province Cancer Hospital.Breast cancer patients in the ER+ group were randomly divided into the experimental subgroup and the control subgroup. The control subgroup was treated with conventional chemotherapy, and the experimental group was additionally given LPI. The effects of immune function, toxic and side effects in the two subgroups were compared.The same process was used for ER-groups.Results Compared with the control subgroup, the total number of T cells, CD4⁺ and CD8⁺ in the ER+ experimental subgroup and in the ER-experimental subgroup were significantly different before and after treatment (P<0.05), and the total number of T cells, CD4⁺ and CD8⁺ were increased after treatment. Compared with the control subgroup,the levels of soluble interleukin receptor-2 (SiL-2R) and malignant tumor specific growth factor (TSGF) in ER+ experimental subgroup were significantly different before and after treatment (P<0.05),and Sil-2R and TSGF decreased. Compared with the control subgroup, Sil-2R decreased significantly in the ER-experimental subgroup.The proportion of severe myelosuppression (grade Ⅲ, IV) was decreased, the proportion of oral mucositis was decreased, and the proportion of severe nausea and vomiting (grade Ⅲ, IV) was significantly reduced. The adverse reactions of high grade were greatly relieved in the ER+ experimental subgroup and in the ER-experimental subgroup.Conclusion It has improved that LPI is effective in improving the immune function, which is worth promoting in the clinical practices.

Key words: lienal polypeptide injection (LPI), estrogen receptor, breast cancer, immune function